

## Phenolic Derivatives from *Dioscorea bulbifera*

Guokai Wang<sup>1</sup>, Juan Zheng<sup>1</sup>, Jaising Yang<sup>2</sup>, Yunpeng Sun<sup>1</sup>,  
Nan Zhang<sup>1</sup>, Huiwen Liu<sup>1</sup> and Jinsong Liu<sup>1\*</sup>

<sup>1</sup> School of Pharmacy & Anhui University of Chinese Medicine; Anhui Innovative Team from Colleges for Scientific Research's Platform-The Innovative Team in Researching the Key Technologies concerning the Integration of Processing Chinese Medicine Decoction Pieces in Producing Area, Hefei, Anhui 230012, P. R. China

<sup>2</sup> Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan

(Received October 22, 2018; Revised November 27, 2018; Accepted December 04, 2018)


**Abstract:** Two new phenolic derivatives, diosbulbiol A (**1**), diosbulbiol B (**2**), and six known compounds were isolated from *Dioscorea bulbifera*. Their structures were determined by MS, IR, UV, 1D- and 2D-NMR. The cytotoxicity of new compounds were evaluated against four cancer cell lines.

**Keywords:** *Dioscorea bulbifera*; dioscorea; cytotoxicity; phenolic derivatives; diosbulbiol A; diosbulbiol B.  
© 2018 ACG Publications. All rights reserved.

### 1. Introduction

*Dioscorea bulbifera* L. (family Dioscoreaceae) is widely distributed in China and used to treat a variety of diseases including thyroid disease and cancer. Previous phytochemical investigations on the root of *D. bulbifera* showed the presence of clerodane diterpenoids [1-3], norclerodane diterpenoids [4], apianen lactones [5], flavonoids and anthraquinones [6]. Our prior study on the plant disclosed the presence of various types of compounds [7-9]. Further investigation resulted in the isolation of two new phenolic derivatives, diosbulbiol A (**1**), diosbulbiol B (**2**), along with six known compounds (**3-8**) from the ethanol extract of the tubers (Figure 1). Compound **1** is a diphenylpentadienone, the diphenylpentadienone derivative biologically activity, for example against leukaemia cells, anti-cancer, anti-allergic, activities [10]. Compound **2** is a diarylheptanoid. Diphenylpentadienone derivative has shown the anti-leishmanial activity [11]. The cytotoxicity of new compounds were evaluated against four cancer cell lines.

\* Corresponding author: E-Mail: [jinsongliu@ahctm.edu.cn](mailto:jinsongliu@ahctm.edu.cn); Phone: +86-551-68129167 Fax: +86-551-68129125



**Figure 1.** Structures of compounds 1-8

## 2. Materials and Methods

### 2.1. General Experimental Procedures

UV spectra were respectively recorded with Shimadzu double-beam 201A equipped with a DAD and a 1cm path-length cell and IR spectra were obtained on a Bruker FT-IR Tensor 27 spectrometer using KBr pellets. Optical rotation was obtained on Jasco P-1020 digital polarimeter. 1D and 2D NMR spectra were run on Bruker DRX-500 and AV-400 spectrometer (Karlsruhe, Germany). Chemical shifts ( $\delta$ ) were expressed in ppm with reference to solvent signals. HREI-MS was measured on a Waters AutoSpec Premier P776 instrument (Waters, Milford, MA, USA). Preparative HPLC was performed using an Agilent 1260 and a reverse-phase C18 column (Agilent Zorbax SB-C18, 150 mm  $\times$  9.4 mm, 5  $\mu$ m, Kyoto, Japan). Column chromatography (CC) was performed on silica gel (200–300 mesh, Qingdao Marine Chemical, Qingdao, China) and Sephadex LH-20 (Amersham Biosciences, Uppsala, Sweden).

### 2.2. Plant Material

The tubers of *D. bulbifera* were collected from Anhui Province, P. R. China, in Sep. 2016 and identified by Qin-Shan Yang, Anhui University of Chinese Medicine. A voucher specimen (No. DB201601) has been deposited in the Department of Natural Products Chemistry, Anhui University of Chinese Medicine.

### 2.3. Extraction and Isolation


Dried crushed tubers (15 kg) of *D. bulbifera* were extracted with 75% EtOH two times (v/v, 2 $\times$ 150 L) at room temperature. The filtrate was concentrated under vacuum to give the extract, which

was suspended in 5 L water and partitioned successively with petroleum ether (6×5 L), EtOAc (6×5 L), and *n*-BuOH (10×5 L). The EtOAc soluble portion (546 g) was subjected to silica gel column chromatography eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:1 to 0:1, v/v) to yield nine fractions, Fr.1–9, based on TLC analysis. Fr. 4 was purified through a prep-HPLC equipped with a ODS-A column (250 × 10 mm) to yield Compound **1** (20 mg), **3** (10 mg), **4** (8 mg). Fr. 5 was subjected to a Sephadex LH-20 column eluted with CHCl<sub>3</sub>/MeOH (1:1, v/v), followed by chromatography over repeated silica gel column (petroleum ether/acetone, 70:30, v/v) to afford Compound **5** (14 mg) and purified a prep-HPLC equipped with a ODS-A column to yield Compound **2** (3 mg), **7** (6 mg) and **8** (7 mg). Fr.9 was subjected to a Sephadex LH-20 column eluted with CHCl<sub>3</sub>/MeOH (1:1, v/v), followed by chromatography over repeated silica gel column (petroleum ether/acetone, 50:50, v/v) to afford Compound **6** (8 mg).

#### 2.4. Spectroscopic Data

*Diosbulbiol A (1)*: Yellow powder. IR<sub>vmax</sub> (KBr): 3430, 2924, 1632, 1120, 588 cm<sup>-1</sup>. UV (MeOH) λ<sub>max</sub> (logε): 367 (3.28), 275(2.86). <sup>1</sup>H (600 MHz, CD<sub>3</sub>OD) and <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): Table 1. HR-ESI-MS *m/z*: [M-H]<sup>-</sup> 295.0614 (calcd. for C<sub>17</sub>H<sub>11</sub>O<sub>5</sub> 295.0612).

*Diosbulbiol B (2)*: Yellow powder. [α]<sub>D</sub><sup>25.5</sup> = -14.55 (C 0.00110, MeOH). IR<sub>vmax</sub> (KBr): 3443, 2925, 1631, 1384, 1030, 586 cm<sup>-1</sup>. UV (CHCl<sub>3</sub>) λ<sub>max</sub> (logε): 203 (3.94), 220 (3.87), 279 (3.77) nm. <sup>1</sup>H (400 MHz, CD<sub>3</sub>OD) and <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD): Table 1. HR-ESI-MS *m/z*: [M+K]<sup>+</sup> 367.0941 (calcd. for C<sub>19</sub>H<sub>20</sub>O<sub>5</sub>K 367.0942).



**Figure 2.** Key <sup>1</sup>H–<sup>1</sup>H COSY and HMBC relevant of compound **1** and **2**

### 3. Results and Discussion

#### 3.1. Structure Elucidation

Compound **1** was obtained as a yellow powder. Its molecular formula C<sub>17</sub>H<sub>12</sub>O<sub>5</sub>, was deduced from the HR-ESI-MS peak at *m/z* 295.0614 [M-H]<sup>-</sup> (*m/z* C<sub>17</sub>H<sub>11</sub>O<sub>5</sub> Calcd for 296.0612), consistent with twelve degrees of unsaturation. The IR spectrum showed absorption bands at 3430 cm<sup>-1</sup> and 1632 cm<sup>-1</sup> ascribed to hydroxyl and benzene ring groups, respectively. The <sup>1</sup>H-NMR spectrum exhibited also signals for benzene ring at δ<sub>H</sub> 6.44 (1H, br.s, H-8), 6.19 (1H, s, H-6) and 7.54 (2H, d, *J* = 8.2 Hz, H-14, H-18), 6.83 (2H, d, *J* = 8.2 Hz, H-15, H-17). Furthermore, the characteristic signals of two double bonds at δ<sub>H</sub> 6.80 (1H, m, H-11), 7.58 (1H, m, H-12), and 6.18 (1H, m, H-10).

The <sup>13</sup>C-NMR and DEPT spectrum of **1** exhibited 17 carbon resonances. including two benzene rings at δ<sub>C</sub> 159.3 (C-5), 165.2 (C-7), 100.0 (C-6), 95.02 (C-8), 105.5(C-4), 163.3 (C-9) and 130.9 (C-15, 17), 128.0 (C-13), 116.9 (C-14, 18), 160.9 (C-16), a carbonyl at δ<sub>C</sub> 183.9 (C-3), and two carbon-carbon double bonds δ<sub>C</sub> 166.3 (C-2), 107.9 (C-10) and 117.3 (C-11), 139.1 (C-12). The <sup>1</sup>H and <sup>13</sup>C NMR spectra (Table 1) of compound **1** was very similar to those of (*Z*)-4, 6-dimethoxy-2-((*E*)-3-phenylallylidene) benzofuran-3(2H)-one [10] with the major differences that a methoxyl group was absent in **1**. After correlation of all the protons with their directly bonded carbon partners via a HSQC

spectrum, it was possible from the HMBC and  $^1\text{H}$ - $^1\text{H}$  COSY spectrum (Figure 2) to deduce the planar structure of **1**. In addition, compared with  $^1\text{H}$ -NMR spectrum and coupling constant, two aromatic ring obtained meta substitution and ortho substitution, respectively. Furthermore, according to the  $^1\text{H}$ - $^1\text{H}$  COSY spectrum, the following cross-peaks H-11/H-12, H-14/H-15 and H-17/H-18 were displayed, for another, in the HMBC spectrum, key long-range correlations were assigned by the HMBC correlations from H-6/C-4, C-8 and H-10/C-2, C-11 and H-1/C-12 and H-15/C-12. Accordingly, the structure of **1** was established as shown in Figure 1 and named Diosbulbiol A.

Compound **2** was obtained as a yellow powder. Its molecular formula  $\text{C}_{19}\text{H}_{20}\text{O}_5$ , was deduced from the HR-ESI-MS peak at  $m/z$  367.0941  $[\text{M}+\text{K}]^+$  (Calcd for  $\text{C}_{19}\text{H}_{20}\text{O}_5$  367.0942), consistent with ten degrees of unsaturation. The IR spectrum showed absorption bands at  $3443\text{ cm}^{-1}$  and  $1631\text{ cm}^{-1}$  ascribed to hydroxyl and benzene ring groups. The  $^1\text{H}$ -NMR spectrum exhibited also signals for benzene ring at  $\delta_{\text{H}}$  7.87 (2H, d,  $J = 8.7\text{ Hz}$ , H-2', H-6'), 6.82 (2H, d,  $J = 8.6\text{ Hz}$ , H-3', H-5') and 7.01 (2H, d,  $J = 8.4\text{ Hz}$ , H-2'', H-6''), 6.68 (2H, d,  $J = 8.4\text{ Hz}$ , H-3'', H-5''). The characteristic signals of a hydroxyl at  $\delta_{\text{H}}$  4.62 (1H, m, H-3).

The  $^{13}\text{C}$ -NMR and DEPT of **2** exhibited 19 carbon resonances (Table 1). The signals were observed due to two benzene rings at  $\delta_{\text{C}}$  130.3 (C-1'), 132.0 (C-2', C-6'), 116.5 (C-3', C-5'), 164.3 (C-4') and 133.2 (C-1''), 130.3 (C-2'', C-6''), 116.2 (C-3'', C-5''), 156.6 (C-4''), a oxymethene at  $\delta_{\text{C}}$  65.9 (C-3), and two carbonyl at  $\delta_{\text{C}}$  199.3 (C-1), 211.4 (C-5). The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra (Table 1) of compound **2** was very similar to those of 5-hydroxy-3-platyphyllone [12]. In addition, comparing that the HRESIMS with **1**, there is 14 mass units more than that of it and suggestive of an carbonyl group of **2**. According to the  $^{13}\text{C}$  NMR spectrum, compound **2** showed that the obvious changes of the chemical shifts were appeared at the C-1 ( $\delta_{\text{C}}$  199.3) rather than it ( $\delta_{\text{C}}$  29.8) in 5-hydroxy-3-platyphyllone This deduction was corroborated by the 2D NMR spectra, in particular the key correlations from H-2' and H-6' to C-1 in the HMBC spectrum. Thus, the planar structure of compound **2** was determined.

**Table 1.** NMR data of compound **1** (500/125 MHz,  $\text{CD}_3\text{OD}$ ) and **2** (400/100 MHz,  $\text{CD}_3\text{OD}$ )

Position	<b>1</b>		No.	<b>2</b>	
	$\delta_{\text{H}}$ ( $J$ in Hz)	$\delta_{\text{C}}$		$\delta_{\text{H}}$ ( $J$ in Hz)	$\delta_{\text{C}}$
1			1		199.3
2		166.3	2	2.78 m	46.3
3		183.9	3	4.62 m	65.9
4		105.5	4	2.67 dd (6.2, 3.6)	50.8
5		159.3	5		211.4
6	6.19 br. s	100.0	6	3.05 dd (8.7, 6.3)	46.0
7		165.2	7	2.78 s	29.8
8	6.44 br. s	95.0	1'		130.3
9		163.3	2'	7.87 d (8.7)	132.0
10	6.18 m	107.9	3'	6.82 d (8.6)	116.5
11	6.80 m	117.3	4'		164.3
12	7.58 m	139.1	5'	6.82 d (8.6)	116.5
13		128.0	6'	7.87 d (8.7)	132.0
14	7.54 d (8.2)	130.9	1''		133.2
15	6.83 d (8.2)	116.9	2''	7.01 d (8.4)	130.3
16		160.9	3''	6.68 d (8.4)	116.2
17	6.83 d (8.2)	116.9	4''		156.6
18	7.54 d (8.2)	130.9	5''	6.68 d (8.4)	116.2
			6''	7.01 d (8.4)	130.3

We had done the experience about the ECD and mosher reactions for identifying this absolutely configuration. The result implied that the absolute configuration at C-3 in **2** was not confirmed due to that was small amounts after separation and purification. Accordingly, the structure of **2** was established as shown in Figure 1 and named Diosbulbiol B.

The known phenolic derivatives was identified as 2', 3-dihydroxy-4, 5-dimethoxybibenzyl (**3**) [13], 2', 3-dihydroxy-5-methoxybibenzyl (**4**) [14], batatasin III (**5**) [15], tristin (**6**) [13], 3-hydroxy-1, 7-bis-(4', 4''-dihydroxyphenyl)-heptane (**7**) [11], platyphyllenone (**8**) [16] by analysis of its spectroscopic and MS data with those reported in this literature.

The new compounds were evaluated *in vitro* for the cytotoxic activities against four cancer cell lines (including SMMC7721, MCF-7, K562 and A549). Unfortunately, none of selected compounds showed obviously inhibitory effect against four cancer cell lines ( $IC_{50} > 40 \mu M$ ).

## Acknowledgments

This research was financially supported by Natural Science Key Research Program of Anhui Province University (No. KJ2015A123).

## Supporting Information

Supporting information accompanies this paper on <http://www.acgpubs.org/journal/records-of-natural-products>

### ORCID

Guokai Wang: [0000-0002-3924-6169](https://orcid.org/0000-0002-3924-6169)

Juan Zheng: [0000-0003-1006-0747](https://orcid.org/0000-0003-1006-0747)

Jaising Yang: [0000-0001-7302-8248](https://orcid.org/0000-0001-7302-8248)

Yunpeng Sun: [0000-0001-6368-0427](https://orcid.org/0000-0001-6368-0427)

Nan Zhang: [0000-0002-3360-2150](https://orcid.org/0000-0002-3360-2150)

Huiwen Liu: [0000-0001-8517-7507](https://orcid.org/0000-0001-8517-7507)

Jinsong Liu: [0000-0002-8982-6719](https://orcid.org/0000-0002-8982-6719)

## References

- [1] R. B. Teponno, A. L. Tapondjou, E. Abou-Mansour, H. Stoeckli-Evans, P. Tane and L. Barboni (2008). Bafoudiosbulbins F and G, further clerodane diterpenoids from *Dioscorea bulbifera* L. var sativa and revised structure of Bafoudiosbulbin B. *Phytochemistry* **69**, 2374-2379.
- [2] R. B. Teponno, A. L. Tapondjou, D. Gatsing, J. D. Djoukeng, E. Abou-Mansour, R. Tabacchi, P. Tane, H. Stoeckli-Evans and D. Lontsi (2006). Bafoudiosbulbins A, and B, two anti-salmonellal clerodane diterpenoids from *Dioscorea bulbifera* L. var sativa. *Phytochemistry* **67**, 1957-1963.
- [3] R. B. Teponno, A. L. Tapondjou, H. Ju-Jung, J. H. Nam, P. Tane and H. J. Park (2007). Three new clerodane diterpenoids from the bulbils of *Dioscorea bulbifera* L. var. sativa. *Helv. Chim. Acta* **90**, 1599-1605.
- [4] Y. Tang, Y. B. Xue, L. Zhou, J. W. Zhang, G. M. Yao, Z. W. Luo, G. Du and Y. H. Zhang (2014). New norclerodane diterpenoids from the tubers of *Dioscorea bulbifera*. *Chem. Pharm. Bull.* **62**, 719-724.
- [5] S. Z. Zheng, Z. Guo, T. Shen, X. D. Zhen and X. W. Shen (2003). Three new apianen lactones from *Dioscorea bulbifera* L. *Indian. J. Chem. – Sect. B* **42**, 946-949.
- [6] S. S. Li, I. A. Iliya, J. Z. Deng and S. X. Zhao (2000). Flavonoids and anthraquinone from *Dioscorea bulbifera* L. *China J. Chin. Mater. Med.* **25**, 159-160.
- [7] G. Wang, J. S. Liu, B. B. Lin, G. K. Wang and J. K. Liu (2009). Two new furanoid norditerpenes from *Dioscorea bulbifera*. *Chem. Pharm. Bull.* **57**, 625-627.
- [8] G. Wang, B. B. Lin, J. S. Liu, G. K. Wang, F. Wang and J. K. Liu (2009). Chemical constituents from tubers of *Dioscorea bulbifera*. *China J. Chin. Mater. Med.* **34**, 1679-1682.
- [9] J. S. Liu, W. N. Gao, J. Zheng, G. K. Wang and Q. S. Yang (2017). Chemical constituents from fresh tubers of *Dioscorea bulbifera*. *China J. Chin. Mater. Med.* **42**, 510-516.
- [10] D. Sharma and J. K. Makrandi (2014). Mercuric acetate mediated oxidative cyclization of (2*E*, 4*E*)-1-(2-hydroxyphenyl)-5- phenylpenta-2, 4-dien-1-ones: Synthesis of (Z)-2-((*E*)-3-phenylallylidene)benzofuran-3(2H)-ones. *J. Heterocyclic. Chem.* **51**, 1818-1820
- [11] C. A. C. Araujo, L. V. Alegrio and L. L. Leon (1998). Antileishmanial activity of compounds extracted and characterized from *Centrolobium sclerophyllum*. *Phytochemistry* **49**, 751-754.

- [12] K. Sunnerheimsjöberg and P. G. Knutsson (1995). Platyphylloside: Metabolism and digestibility reduction in vitro. *J. Chem. Ecol.* **21**, 1339-1348.
- [13] L. M. Li, G. Q. Li, X. Wu, G. C. Wang and Y. L. Li (2014). Stilbenoids from rhizomes of *Dioscorea bulbifera*. *Chin. Trad. Herbal. Drugs.* **45**, 328-332.
- [14] Y. W. Leong, C. C. Kang, L. J. Harrison and A. D. Powell (1997). Phenanthrenes, dihydrophenanthrenes and bibenzyls from the orchid *bulbophyllum vaginatum*. *Phytochemistry* **44**, 157-165.
- [15] Y. G. Chen, H. Yu and X. Lian (2015). Isolation of stilbenoids and lignans from *Dendrobium hongdie*. *Tropical J. Pharm. Res.* **14**, 2055
- [16] N. H. Tung, S. K. Kim and J. C. Ra (2010). Antioxidative and hepatoprotective diarylheptanoids from the bark of *Alnus japonica*. *Planta. Med.* **76**, 626-629

**A C G**  
**publications**

© 2018 ACG Publications